MX2020012291A - Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. - Google Patents

Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.

Info

Publication number
MX2020012291A
MX2020012291A MX2020012291A MX2020012291A MX2020012291A MX 2020012291 A MX2020012291 A MX 2020012291A MX 2020012291 A MX2020012291 A MX 2020012291A MX 2020012291 A MX2020012291 A MX 2020012291A MX 2020012291 A MX2020012291 A MX 2020012291A
Authority
MX
Mexico
Prior art keywords
negative breast
triple negative
compounds
treatment
cancer
Prior art date
Application number
MX2020012291A
Other languages
English (en)
Inventor
Mitchell S Steiner
Wei Li
Miller Duane D
Shanshan Deng
Raya Krutilina
Tiffany Seagroves
Junming Yue
Guannan Zhao
Wang Qinghui
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of MX2020012291A publication Critical patent/MX2020012291A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención abarca los métodos para tratar el cáncer de mama triple negativo y/o el cáncer de ovario mediante el uso de cantidades terapéuticamente efectivas de compuestos representados por la estructura de fórmula I.
MX2020012291A 2018-05-15 2019-05-15 Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. MX2020012291A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671824P 2018-05-15 2018-05-15
US201862741494P 2018-10-04 2018-10-04
US201962805826P 2019-02-14 2019-02-14
PCT/US2019/032468 WO2019222385A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of triple negative breast cancer and ovarian cancer

Publications (1)

Publication Number Publication Date
MX2020012291A true MX2020012291A (es) 2021-03-25

Family

ID=68540988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012291A MX2020012291A (es) 2018-05-15 2019-05-15 Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.

Country Status (10)

Country Link
US (1) US20190389841A1 (es)
EP (1) EP3793549A4 (es)
JP (1) JP7114745B2 (es)
KR (1) KR20210020022A (es)
CN (1) CN112512522A (es)
AU (1) AU2019270089B2 (es)
CA (1) CA3099919A1 (es)
MX (1) MX2020012291A (es)
UA (1) UA125551C2 (es)
WO (1) WO2019222385A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041744A1 (en) * 2019-08-30 2021-03-04 University Of Tennessee Research Foundation Ryl benzoyl imidazole compounds for the treatment of lung cancer
JOP20220138A1 (ar) * 2020-04-03 2023-01-30 Veru Inc طرق مُعالجة فيروس كورونا
CN117396505A (zh) * 2021-04-05 2024-01-12 维鲁公司 治疗炎症的方法
WO2023089632A1 (en) * 2021-11-16 2023-05-25 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Pyrazole amide based compounds and uses against breast cancer thereof
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN114805307B (zh) * 2022-04-29 2024-08-09 南京雷正医药科技有限公司 一种用于制备冠状病毒治疗药物的吲哚类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
PT2959900T (pt) 2008-06-16 2017-06-22 Univ Tennessee Res Found Composto para tratamento do cancro
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
JP4643734B1 (ja) 2009-08-12 2011-03-02 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム
CN102883607B (zh) * 2010-03-01 2015-07-22 Gtx公司 用于治疗癌的化合物
AU2011293353B2 (en) 2010-08-24 2015-02-26 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
AU2014207641A1 (en) * 2013-01-16 2015-08-06 Signal Pharmaceuticals, Llc Substituted Pyrrolopyrimidine Compounds, compositions thereof, and methods of treatment therewith
MX2015011713A (es) * 2013-03-05 2016-05-09 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.

Also Published As

Publication number Publication date
JP7114745B2 (ja) 2022-08-08
EP3793549A1 (en) 2021-03-24
WO2019222385A1 (en) 2019-11-21
KR20210020022A (ko) 2021-02-23
CN112512522A (zh) 2021-03-16
EP3793549A4 (en) 2022-03-09
AU2019270089B2 (en) 2022-11-10
AU2019270089A1 (en) 2020-12-24
US20190389841A1 (en) 2019-12-26
JP2021523204A (ja) 2021-09-02
UA125551C2 (uk) 2022-04-13
CA3099919A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12020500655A1 (en) Compounds
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2021014286A (es) Proteinas multiespecificas.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
EA201692472A1 (ru) Соединения для лечения рака мозга
PH12017501879A1 (en) Methods for treating cancer
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
PH12019550224A1 (en) Antitumoral compounds
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
EA201992557A1 (ru) Противоопухолевые соединения